BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Congenital Adrenal Hyperplasia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Congenital Adrenal Hy
 perplasia\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07947368-10814@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Crinecerfont: Phase 3 readout est. (NCT07947368)
DESCRIPTION:Crinecerfont\, phase 3\, Congenital Adrenal Hyperplasia.\nStudy
 : Study to Evaluate the Effect of Crinecerfont on Androgen Reduction and R
 elated Outcomes in Adults With Classic Congenital Adrenal Hyperplasia (CAH
 )\nEstimated primary completion: January 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/crinecerfont#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07947368
URL:https://assetmemo.bio/drug/crinecerfont#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07536269-10814@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Crinecerfont: Phase 2 readout est. (NCT07536269)
DESCRIPTION:Crinecerfont\, phase 2\, Congenital Adrenal Hyperplasia.\nStudy
 : Safety\, Tolerability\, Pharmacokinetics and Pharmacodynamics of Crinece
 rfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Wh
 o Are Less Than 4 Years Old\nEstimated primary completion: March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/crinecerfont#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07536269
URL:https://assetmemo.bio/drug/crinecerfont#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187375-10814@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20290906
DTEND;VALUE=DATE:20290907
SUMMARY:Crinecerfont: Phase 2 readout est. (NCT07187375)
DESCRIPTION:Crinecerfont\, phase 2\, Congenital Adrenal Hyperplasia.\nStudy
 : Pharmacokinetics\, Safety and Tolerability of Crinecerfont in Participan
 ts With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old\nEsti
 mated primary completion: 6 September 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/crinecerfont#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07187375
URL:https://assetmemo.bio/drug/crinecerfont#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
